Adaptive randomization of veliparib-carboplatin treatment in breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Benzimidazoles
  • Carboplatin
  • Triple Negative Breast Neoplasms

abstract

  • The process used in our trial showed that veliparib-carboplatin added to standard therapy resulted in higher rates of pathological complete response than standard therapy alone specifically in triple-negative breast cancer. (Funded by the QuantumLeap Healthcare Collaborative and others; I-SPY 2 TRIAL ClinicalTrials.gov number, NCT01042379.).

authors

publication date

  • July 7, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5259561

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1513749

PubMed ID

  • 27406347

Additional Document Info

start page

  • 23

end page

  • 34

volume

  • 375

number

  • 1